Leadership changes at Femasys Inc (2026)

Departing: Kenneth D. Eichenbaum, Director

On October 30, 2026, Kenneth D. Eichenbaum, M.D., M.S.E. , informed the Board of Directors (the "Board") of Femasys Inc. (the "Company") of his resignation as a director of the Company, effective as of that date.

Appointed: John Moorhead, Director

On October 30, 2026, the Board appointed John Moorhead as a director of the Company, effective as of that date.

Appointed: John Moorhead

Mr. Moorhead was appointed to the Board pursuant to the board designation rights granted to Nantahala Capital Management, LLC (the "Lead Investor") under the side letter agreement, dated as of August 7, 2026 (the "Side Letter"), between the Company and the Lead Investor, pursuant to which the Company agreed to appoint up to two individuals designated by the Lead Investor to serve on the Board.

Also stated in this filing

• Dr. Eichenbaum's resignation was in connection with Pointillist Global Macro Series of Pointillist Partners LLC's termination of its right to nominate an individual to serve on the Board pursuant to that certain Securities Purchase Agreement, dated November 3, 2025, by and among the Company and certain accredited investors.
• Dr. Eichenbaum's decision to resign was not due to any dispute or disagreement with the Company, or on any matter relating to the Company's operations, policies or practices.
• The Lead Investor's right to designate designees is subject to certain minimum ownership thresholds of the Company's outstanding common stock set forth in the Side Letter.
• Mr. Moorhead will be entitled to the applicable annual retainer and equity awards pursuant to the Company's director compensation policy, under terms consistent with those previously disclosed by the Company.
• Mr. Moorhead will also be entitled to enter into an indemnification agreement with the Company.
• Mr. Moorhead will hold office as a Class II director for a term expiring at the 2029 annual meeting, at which time he will stand for election by the stockholders of the Company.
• The Board determined that Mr. Moorhead is an independent director for purposes of the Nasdaq listing requirements and will serve as a member of the Audit Committee and Compensation Committee of the Company.

Reported

(c) On April 1, 2026, Femasys Inc. (the "Company") announced the hiring and appointment of John Canning as its Chief Operating Officer, effective March 30, 2026.

Also stated in this filing

• Mr. Canning, age 52, most recently served as Chief Operating Officer at Terumo Aortic from April 2017 to February 2026, where he led global operations and technology functions.
• Prior to that he held senior leadership roles at Bolton Medical from 2003 to 2017, including Chief Operating Officer and was instrumental in Terumo's acquisition of Bolton Medical.
• Earlier in his career, he held manufacturing operations leadership positions at Medtronic from 1999 to 2003.
• Mr. Canning holds a B.S. in Mechanical Engineering from College of New Jersey.
• The Company entered into an employment agreement (the "Employment Agreement") with Mr. Canning in connection with his appointment as Chief Operating Officer.
• Under the Employment Agreement, which is effective March 30, 2026, Mr. Canning will receive an annual base salary of $450,000 and he will be eligible to participate in the Company's annual bonus program, with a target bonus of 40% of his base salary.
• The Inducement Award will vest as to 25% of the shares underlying the stock option on the first anniversary of the commencement of employment, with the remaining shares vesting 25% each year over the following three years, subject to Mr. Canning's continued employment with the Company.
• Mr. Canning will also be eligible to receive such future long-term incentive awards as the Board of Directors shall deem appropriate.